Can Namenda (memantine) and Aricept (donepezil) be given to a patient with Parkinson's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 11, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Donepezil and Memantine in Parkinson's Disease

Donepezil (Aricept) and memantine (Namenda) can be given to patients with Parkinson's disease, particularly those with cognitive impairment, though memantine should be used with caution as it shows limited benefit in Parkinson's disease mild cognitive impairment.

Efficacy of Cholinesterase Inhibitors in Parkinson's Disease

Donepezil (Aricept) has demonstrated beneficial effects in Parkinson's disease patients with cognitive impairment:

  • Donepezil shows selective and significant improvement on memory in Parkinson's disease patients with cognitive impairment 1
  • Patients with less decrease in acetylcholinesterase (the binding site of donepezil) show better improvement in visuoperceptual function after donepezil therapy 2

Efficacy of Memantine in Parkinson's Disease

Memantine (Namenda) shows mixed results in Parkinson's disease:

  • For Parkinson's Disease Dementia (PDD), memantine did not show significant differences compared to placebo in clinical global impression of change scores 3
  • However, in patients with Dementia with Lewy Bodies (DLB), memantine demonstrated greater improvement in clinical global impression of change scores and neuropsychiatric inventory scores compared to placebo 3
  • A more recent study (2022) found that memantine did not improve visuospatial working memory in patients with Parkinson's disease mild cognitive impairment (PD-MCI) and may even worsen certain cognitive functions 4

Combination Therapy Considerations

The American Academy of Neurology and American Geriatrics Society recommend:

  • Combination of memantine and a cholinesterase inhibitor may be beneficial in moderate to severe Alzheimer's disease 5
  • The combination shows superior outcomes compared to cholinesterase inhibitor monotherapy in terms of cognition, activities of daily living, and behavior 5

Safety and Tolerability

Donepezil

  • Common adverse events include gastrointestinal symptoms (nausea, vomiting, diarrhea), neurological symptoms (dizziness, headache, insomnia), and cardiovascular symptoms (bradycardia, syncope) 5
  • In Parkinson's disease specifically, variable tolerability has been observed with 4 out of 7 patients withdrawing due to adverse effects in one study, including increased parkinsonism in one patient 1

Memantine

  • Common adverse events include headache, dizziness, diarrhea, and confusion 5
  • In patients with renal impairment, dosage adjustment is necessary as memantine clearance decreases with declining renal function 6

Pharmacokinetic Interactions

  • Coadministration of memantine with donepezil does not affect the pharmacokinetics of either compound 6
  • Memantine does not affect acetylcholinesterase inhibition by donepezil 6
  • The adverse event profile with combination therapy is similar to that of donepezil alone 6

Practical Recommendations

  1. For Parkinson's disease with cognitive impairment:

    • Start with donepezil at 5 mg once daily for 4-6 weeks
    • If tolerated, increase to 10 mg once daily (optimal therapeutic dose)
    • Monitor closely for worsening of motor symptoms and peripheral cholinergic effects

  2. For Parkinson's disease with dementia (PDD):

    • Donepezil remains a reasonable first choice
    • Consider adding memantine only in moderate to severe cases
    • Start memantine at low dose (5 mg daily) and titrate gradually to 20 mg daily

  3. For patients with Dementia with Lewy Bodies (DLB):

    • Both donepezil and memantine may be beneficial
    • Memantine has shown specific benefits for behavioral symptoms in DLB 3

Common Pitfalls to Avoid

  1. Rapid titration: Increase doses gradually to minimize side effects, especially in Parkinson's disease patients who may be more sensitive to adverse effects

  2. Ignoring renal function: Memantine requires dosage adjustment in severe renal impairment 6

  3. Overlooking worsening of parkinsonism: Monitor carefully for exacerbation of motor symptoms, especially when initiating or increasing donepezil 1

  4. Continuing ineffective treatment: Assess response after 3-6 months using objective measures of cognition, function, and behavior 5

  5. Expecting benefits in mild cognitive impairment: Memantine has not shown benefits and may even worsen certain cognitive functions in PD-MCI 4

References

5
Guideline

Treatment of Alzheimer's Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the starting dose of Namenda (memantine) for a patient with Parkinson's disease?
What is the classification system for mammography?
Can a urine sample be taken directly from an ileoconduit (ileal conduit) to check for infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question